精華(hua)制(zhi)(zhi)藥集團(tuan)股份有(you)限(xian)公(gong)司是由南通產控集團(tuan)控股、國(guo)資監管的地方國(guo)有(you)控股企業,由原南通中誠制(zhi)(zhi)藥有(you)限(xian)公(gong)司(南通中藥廠)變(bian)更、重(zhong)組(zu)南通制(zhi)(zhi)藥總廠(南通制(zhi)(zhi)藥廠、南通制(zhi)(zhi)藥二廠)優質資源,并吸收民(min)營資本南通綜(zong)藝(yi)投(tou)資有(you)限(xian)公(gong)司以及自(zi)然人投(tou)資設立(li)。2010年2月在(zai)深(shen)交所中小板掛(gua)牌上市,股票簡稱:精華(hua)制(zhi)(zhi)藥,證券代號:002349。
公(gong)(gong)司(si)已有(you)(you)(you)(you)60多年的(de)(de)制(zhi)藥(yao)(yao)(yao)(yao)歷(li)史,是(shi)一(yi)(yi)家(jia)(jia)綜合性的(de)(de)現(xian)代化(hua)GMP制(zhi)藥(yao)(yao)(yao)(yao)有(you)(you)(you)(you)限公(gong)(gong)司(si)。目前擁有(you)(you)(you)(you)7個(ge)子公(gong)(gong)司(si),是(shi)一(yi)(yi)家(jia)(jia)集(ji)中(zhong)藥(yao)(yao)(yao)(yao)制(zhi)劑(ji)、中(zhong)藥(yao)(yao)(yao)(yao)飲(yin)片、西(xi)(xi)藥(yao)(yao)(yao)(yao)制(zhi)劑(ji)、醫藥(yao)(yao)(yao)(yao)中(zhong)間(jian)體、化(hua)學原料藥(yao)(yao)(yao)(yao)、生物制(zhi)藥(yao)(yao)(yao)(yao)、保(bao)(bao)健品(pin)(pin)(pin)(pin)(pin)(pin)等生產(chan)(chan)、銷售和研發的(de)(de)綜合型制(zhi)藥(yao)(yao)(yao)(yao)企(qi)業(ye)集(ji)團。公(gong)(gong)司(si)有(you)(you)(you)(you)中(zhong)西(xi)(xi)藥(yao)(yao)(yao)(yao)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)200余種(zhong)(zhong)(zhong),中(zhong)藥(yao)(yao)(yao)(yao)產(chan)(chan)品(pin)(pin)(pin)(pin)(pin)(pin)主(zhu)要有(you)(you)(you)(you)享譽海內外的(de)(de)經典名藥(yao)(yao)(yao)(yao)“五朵金花(hua)”王氏保(bao)(bao)赤丸(wan)、季德(de)勝(sheng)蛇藥(yao)(yao)(yao)(yao)片、正柴胡(hu)飲(yin)顆(ke)粒、大(da)柴胡(hu)顆(ke)粒、金蕎麥膠(jiao)囊,以及(ji)(ji)固本咳喘片、暈(yun)可(ke)平糖漿、精血(xue)補片等,這些中(zhong)藥(yao)(yao)(yao)(yao)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)都有(you)(you)(you)(you)著廣泛的(de)(de)歷(li)史背景及(ji)(ji)深厚的(de)(de)文化(hua)底蘊,其中(zhong)季德(de)勝(sheng)蛇藥(yao)(yao)(yao)(yao)片、王氏保(bao)(bao)赤丸(wan)制(zhi)作(zuo)技藝均被(bei)列入國(guo)家(jia)(jia)非物質文化(hua)遺產(chan)(chan)。原料藥(yao)(yao)(yao)(yao)產(chan)(chan)品(pin)(pin)(pin)(pin)(pin)(pin)主(zhu)要有(you)(you)(you)(you)苯(ben)巴比妥、撲米酮、氟(fu)尿嘧(mi)啶(ding)、保(bao)(bao)泰松(song)、氟(fu)胞嘧(mi)啶(ding)、吡(bi)羅昔康(kang)、替(ti)諾昔康(kang)、丙硫(liu)氧(yang)嘧(mi)啶(ding)、非那西(xi)(xi)丁、雙嘧(mi)達莫以及(ji)(ji)其它醫藥(yao)(yao)(yao)(yao)中(zhong)間(jian)體等。其中(zhong)已有(you)(you)(you)(you)10個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)通(tong)過(guo)(guo)國(guo)家(jia)(jia)GMP認證(zheng),5個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)通(tong)過(guo)(guo)歐盟CEP認證(zheng),2個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)通(tong)過(guo)(guo)澳大(da)利亞(ya)GMP認證(zheng),3個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)通(tong)過(guo)(guo)墨西(xi)(xi)哥官方(fang)認證(zheng),4個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)獲(huo)得(de)(de)美國(guo)DMF注冊文件 ,1個(ge)品(pin)(pin)(pin)(pin)(pin)(pin)種(zhong)(zhong)(zhong)獲(huo)得(de)(de)美國(guo)VMF注冊文件,并已通(tong)過(guo)(guo)美國(guo)FDA現(xian)場核(he)查。
精華制藥(yao)將(jiang)會以(yi)“成為(wei)(wei)以(yi)傳世中藥(yao)為(wei)(wei)核(he)心特(te)(te)色(se)的全國(guo)現代醫藥(yao)企業”為(wei)(wei)戰(zhan)略(lve)目標,深入貫(guan)徹《關于促進中醫藥(yao)傳承創新發展(zhan)的意見》精神,聚焦“五朵金花”傳世中藥(yao)主業為(wei)(wei)主,特(te)(te)色(se)化學(xue)(xue)原料藥(yao)及化學(xue)(xue)制劑為(wei)(wei)輔的“雙(shuang)輪驅(qu)動”的發展(zhan)戰(zhan)略(lve),依(yi)托品(pin)牌力(li)和渠道力(li),致力(li)于成為(wei)(wei)以(yi)傳世中藥(yao)為(wei)(wei)核(he)心特(te)(te)色(se)的全國(guo)現代醫藥(yao)企業。